Trial Profile
Phase I Clinical Study of Crenezumab in Patients with Alzheimer's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Crenezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 12 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Jun 2016 New trial record
- 10 Jun 2016 Status changed from not yet recruiting to recruiting.